

POST-TEST

Existing and Emerging Strategies in the Management of Patients with Uterine Sarcomas

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following descriptions correctly cites the mechanism of action of trabectedin?
 - DNA binding/damaging agent
 - Immune checkpoint inhibitor
 - Tyrosine kinase inhibitor
- The results of the Phase III ET743-SAR-3007 trial comparing trabectedin to dacarbazine for patients with previously treated advanced liposarcoma or leiomyosarcoma demonstrated a statistically significant improvement in _____ with trabectedin.
 - Progression-free survival
 - Overall survival
 - Both a and b
- Olaratumab, an agent recently FDA approved in combination with doxorubicin for adult patients with soft tissue sarcoma that cannot be cured with radiation therapy or surgery, is _____.
 - An immune checkpoint inhibitor
 - An anti-PDGFR alpha monoclonal antibody
 - A tyrosine kinase inhibitor
- The ongoing Phase III ANNOUNCE trial is evaluating _____ and doxorubicin versus placebo and doxorubicin for patients with anthracycline-naïve advanced or metastatic unresectable soft tissue sarcoma.
 - Eribulin
 - Regorafenib
 - Olaratumab
- Data from the GOG-40 study of prognostic factors in early-stage uterine sarcoma indicated that the recurrence rate for leiomyosarcoma was 71%, with _____ of recurrences occurring in the pelvis.
 - 3%
 - 5%
 - 14%
- Data from the GOG-20 and EORTC-GCG 55874 studies of pelvic radiation therapy for uterine sarcoma demonstrated a modest decrease in local relapses among patients with _____.
 - Leiomyosarcoma
 - Carcinosarcoma
 - Neither a nor b
- The randomized Phase II UC1644 study will evaluate _____ versus observation for patients with newly diagnosed uterine leiomyosarcoma.
 - Chemotherapy
 - Chemotherapy with or without radiation therapy
 - Letrozole
- The Phase II Alliance A091401 trial is evaluating _____ as treatment for metastatic or unresectable sarcoma.
 - Nivolumab with or without ipilimumab
 - Alisertib
 - Durvalumab
 - Atezolizumab
- Data from the randomized Phase III GOG-87L trial of gemcitabine and docetaxel for first-line, measurable uterine leiomyosarcoma demonstrated a response rate of approximately _____.
 - 14%
 - 36%
 - 62%
- The results of the GeDDIS trial of gemcitabine/docetaxel as first-line treatment for locally advanced or metastatic soft tissue sarcoma demonstrated a statistically significant overall survival advantage with gemcitabine/docetaxel compared to standard doxorubicin therapy.
 - True
 - False